News

With its shares more than doubling in 2023, Advanced Micro Devices (NASDAQ: AMD) has been a rewarding near-term investment. While the company's operational results are yet to match its impressive

The success of drug developers hinges on regulatory approvals for their medications. Considering that, it was hardly surprising that Pfizer (NYSE: PFE) stock had a good Monday on the market

Per updated guidance for its upcoming 2024 fiscal year, issued on Dec. 13, Pfizer (NYSE: PFE) has a bumpy road ahead -- at least for now. Amidst rapidly weakening coronavirus product revenue and

Altria (NYSE: MO) and AT&T (NYSE: T) are two big names for many dividend investors, and it's no mystery why. While both stocks are trailing the S&P 500 over the past five years, they offer two of

Many investors will likely be wearing big smiles as 2023 winds down. The S&P 500 is on track to deliver a gain of over 20% and could hit an all-time high. The Nasdaq-100 has soared more than 50% and

Dividend stocks can offer a valuable source of income for investors who want to diversify their portfolios. However, investors should also be aware that most of these stocks will gradually decline

The word "revolutionary" sometimes gets thrown around a lot, but it certainly applies to Sarepta Therapeutics (NASDAQ: SRPT). This midcap biotech company has developed several treatments for

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen

Earlier in the pandemic, Pfizer (NYSE: PFE) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on

Telecom veteran AT&T (NYSE: T) has delivered dividends to investors for decades. Rival T-Mobile (NASDAQ: TMUS) followed suit in 2023, offering a dividend for the first time in company history with

Fool.com contributor Parkev Tatevosian reviews AT&T (NYSE: T) from the viewpoint of a passive income investor to determine whether it's an excellent dividend stock to buy.

*Stock prices used were

Fool.com contributor Parkev Tatevosian discusses a new arrangement between Rivian (NASDAQ: RIVN) and AT&T (NYSE: T) that has potential benefits for Rivian shareholders.

*Stock prices used were the

On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light

Having at least $1 million in the bank by retirement has long been a popular goal, but it isn't easy to accomplish. One of the best ways to do so is to invest in stocks, and the earlier one starts

You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the

It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in

Good news became bad news for Rocket Lab USA (NASDAQ: RKLB) on Friday after the company announced its successful return to launch operations for the first time since a mishap resulted in the

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

If there has been an overarching investment theme in 2023, it has probably been artificial intelligence (AI). Ever since the conversational chatbot ChatGPT launched in late 2022, tech giants have

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

Many aggressive growth stocks are rising Thursday as Treasury yields drop and investors anticipate Federal Reserve rate cuts ahead. But shares of electric vehicle maker Rivian Automotive (NASDAQ:

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying